Alexander, Morgan L.
Alagapan, Sankaraleengam
Lugo, Courtney E.
Mellin, Juliann M.
Lustenberger, Caroline
Rubinow, David R.
Fröhlich, Flavio http://orcid.org/0000-0002-3724-5621
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P300PA_164693)
Article History
Received: 29 September 2018
Revised: 11 February 2019
Accepted: 13 February 2019
First Online: 5 March 2019
Conflict of interest
: F.F. is the lead inventor of an IP filed by UNC. The clinical studies performed in the Frohlich Lab have originally received a designation as conflict of interest with administrative considerations that was subsequently removed. F.F. is the founder, CSO, and majority owner of Pulvinar Neuro LLC. The company had no role in this study. F.F. is also an author under Elsevier and receives royalty payments. D.R.R. reports consulting fees, travel reimbursement, and stock options as a member of the Clinical Advisory Board of Sage Therapeutics. D.R.R. also received compensation as a member of the Editorial Board of Dialogues in Clinical Neurosciences (Servier). All other authors declare that they have no conflict of interest.